Superworth

PMGC ELAB

Drug Manufacturers - General, Healthcare
$2.71
+1.72%
Market cap
$2.2M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
0.8×
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
$2.6M
Net margin
n/m
outside −100% to 100%
Free cash flow yield
n/m
not a meaningful number

PMGC trades at 0.8× sales. Revenue was $2.6M over the last twelve months.

Charts

Financials

Income statement for ELAB, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$554.7K−100%n/a$614.6K+330%$605.5K+91%$527.5K−5%n/an/an/a$285.9K−46%$304.1K$682K$1.3M
Cost of revenue$188.5K−100%n/a$168.9K+280%$166.3K+54%$133.6K−29%n/an/an/a$207.9K+56%$196.9K$451.5K$920.9K
Gross profit$366.1K−100%n/a$445.7K+353%$439.3K+111%$393.9K+8%n/an/an/a$78K−80%$107.3K$230.5K$385.7K
R&D$86.4K−100%n/a$2.8K−97%$34.8K−74%$4.1K−95%$45K$32.4K+1066%$66.7K+92%$15K+266%$32.9K−27%$47.1K+45%$310.2K+365%
SG&A$764.6K−100%n/a$264K−51%$281.9K−56%$178.3K−77%$660.9K$244.6K−7%$402.2K+43%$791K+344%$1M+52%$1.4M+479%$1.6M+306%
−$785.6Kn/a−$1.7M+99%−$1.4M+34%−$625.6K−20%−$1.3Mn/an/a−$2.2M+252%−$2.9M+123%n/an/a
Interest expense$5.7K−99%n/a$19.2K+627%$23.6K+435%$641.8K+11134%$50.6K$10.5K−45%$2−100%$17.4K−97%$229.8K+354%$474.2K+4427%$582.2K+29111950%
Net income−$783K−100%−$1.2M−$1.4M+29%−$1.4M+10%−$1.5M+92%−$1.9M+67%−$1.6M+15%−$562.4K−60%−$2.6M+73%−$3M+54%−$5M+209%−$2.9M+423%
−$91728000.00−$100.80−$36907.08−$35534.52−$63786.96−100%n/a−$2437.64−93%−$391.38−99%−$1188.00−98%n/a−$112.19−95%−$6.07−98%
011.3K151619+220970%n/a649+4299%1.5K+9416%2.2K+11587%n/a44.5K+6754%487.6K+32836%

Operating income: Q4 FY24 and Q4 FY25: not printed by the filing, worked out from its own lines.

Interest expense: Q1 FY23: 6 months less the 3 months printed beside them.

EPS, diluted: Q4 FY23: quarter's net income to common over its shares, to the cent.

Diluted shares: 10 periods, Q3 FY23 to Q2 FY26: not printed by the filing, worked out from its own lines.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest PMGC's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
ELABPMGC$2.2Mn/mn/a0.8×n/mn/m
OXBROXBRIDGE RE HOLDINGS$7.7M47.5×9.6×2.8×+40%4.7%
EDUCEducational Development$8.7M5.4×11.3×0.4×−32%8.6%
GTIMGood Times Restaurants$13.6M6.1×13.6×0.1×−6%1.7%
MDRRMedalist Diversified$15.4M2.5×3.0×1.6×−1%80.2%
BCGBinah Capital$18.2M6.7×20.8×0.1×+8%2.2%
VIPVulcan Infrastructure & Power$19.6M17.9×24.4×0.4×−14%1.0%
MXCMexco Energy$20.5M13.4×13.3×3.0×−9%23.3%
CKXCKX Lands$21.5M7.4×32.6×31.0×−17%n/m
Peer median$16.8M7.0×13.4×1.0×−7%4.7%

More on PMGC

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .